<DOC>
	<DOCNO>NCT02138617</DOCNO>
	<brief_summary>This study involve standard combination chemotherapy treatment colon cancer , 5-Fluorouracil ( 5FU ) , leucovorin irinotecan ( know FOLFIRI ) , plus bevacizumab ( Avastin ) . The study design test FOLFIRI regimen base certain characteristic person 's genetic makeup `` gene '' . Genes make DNA determine inherit trait appearance ( hair eye color , height , body type , etc . ) also play important role health body respond illness treatment illness . In study , investigator examine relationship patient 's gene ( DNA ) , `` genotype '' , patient 's body break remove `` metabolizes '' anti-cancer drug irinotecan . Circulating blood level irinotecan play important role well drug work patient 's cancer well adverse side effect patient may experience . The current standard dose irinotecan determine clinical trial without know individual genotype thus take account patient 's ability metabolize irinotecan . This mean base one genotype current standard dose irinotecan may correct base genotype standard dose could result low possibly less effective blood level result significant under-dosing irinotecan . Based genotype patient assign one follow dos irinotecan : - 180 mg/m2 ( standard dose ) - 260 mg/m2 - 310 mg/m2 The purpose research study determine dose irinotecan base genotype effective safe patient colon cancer . Patient genotype determine small sample blood laboratory test `` assay '' perform UNC Laboratories . For purpose study , assay new consider `` investigational '' . This mean genotype assay use study yet approve FDA determine irinotecan dose level patient colon cancer .</brief_summary>
	<brief_title>Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer</brief_title>
	<detailed_description>This phase II multicenter clinical trial use genotype-guided dosing strategy irinotecan prospectively analyze efficacy 100 metastatic colorectal cancer patient ( mCRC ) receive FOLFIRI ( 5-fluorouracil ( 5-FU ) , leucovorin , irinotecan ) plus bevacizumab . Irinotecan detoxify excrete primarily glucuronidation liver via isoenzyme uridine diphosphate glucuronosyl transferase ( UGT1A1 ) . Common variant UGT1A1 alter rate glucuronidation thus alter exposure irinotecan . The UGT1A1 *28 allele result slow irinotecan glucuronidation , thus great exposure active metabolite SN-38 . At standard irinotecan dose use FOLFIRI ( 180 mg/m2 ; establish prior understanding importance genotype rate drug 's metabolism ) , small increase risk neutropenia *28 homozygotes . However , risk clinically important consequence neutropenia , febrile neutropenia infection , significantly increase . Patients genotypes quite low risk adverse effect suggest patient low risk genotype may tolerate high dos irinotecan FOLFIRI . This finding demonstrate phase I study *1/*28 *1/*1 genotype able tolerate escalate dos irinotecan 260 mg/m2 310 mg/m2 , respectively . The central hypothesis trial increase irinotecan dose *1/*28 *1/*1 genotypes increase overall benefit FOLFIRI patient mCRC two group likely under-dosed current dose regimen . Eligible patient genotyped UGT1A1 assign 1 3 different dose group , base relative rate metabolism . The primary objective trial estimate progression-free survival ( PFS ) , secondary objective include characterization toxicity objective response rate ( OR ; complete response ( CR ) + partial response ( PR ) ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Subjects must meet inclusion criterion participate study : 1 . IRBapproved informed consent obtain sign 2 . Age ≥ 18 year 3 . Histological cytological documentation adenocarcinoma colon rectum 4 . Measurable nonmeasurable ( evaluable ) disease define via RECIST 1.1 5 . Metastatic disease amenable surgical resection curative intent 6 . No prior chemotherapy metastatic disease 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 ( see section 11.1 , Appendix A ) 8 . Adequate bone marrow , renal hepatic function , evidence following : absolute neutrophil count ( ANC ) ≥1,500/mm3 platelet ≥100,000/mm3 hemoglobin ≥9.0 g/dL serum creatinine ≤1.5 x upper limit normal ( ULN ) AST ALT ≤3x ULN ( ≤5.0 × ULN patient liver involvement cancer Bilirubin ≤1.5 X ULN Alkaline phosphatase ≤3 x ULN ( ≤5 x ULN liver involvement cancer ) 9 . Willing undergo UGT1A1 genotyping 10 . Negative pregnancy test ( urine serum ) , within 7 day prior Day 1 FOLFIRI woman childbearing potential 11 . Women childbearing potential male subject must agree use adequate contraception duration study participation . Adequate contraception define medically recommend method ( combination method ) per standard care . Exclusion Criteria 1 . UGT1A1 genotype *1/*1 , *1/*28 , *28/*28 2 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency 3 . Prior treatment irinotecan and/or bevacizumab 4 . Unable unwilling discontinue ( substitute necessary ) use prohibit drug least 14 day ( fruits juice least 7 day ) prior Day 1 FOLFIRI + bevacizumab initiation ( see section 11.2 , Appendix B , list prohibit drug ) 5 . Inadequately control hypertension ( define systolic blood pressure &gt; 140 mmHg and/or diastolic blood pressure &gt; 90 mmHg ) 6 . Prior history hypertensive encephalopathy 7 . Active cardiac disease include follow : New York Heart Association ( NYHA ) Grade II great congestive heart failure ( see section 11.3 , Appendix C ) History myocardial infarction unstable angina within 6 month prior Day 1 History stroke transient ischemic attack within 6 month prior Day 1 FOLFIRI + bevacizumab initiation 8 . Significant vascular disease ( e.g. , aortic aneurysm , require surgical repair recent peripheral arterial thrombosis ) within 6 month prior Day 1 FOLFIRI + bevacizumab initiation 9 . History hemoptysis ( ≥ 1/2 teaspoon bright red blood per episode ) within 1 month prior Day 1 FOLFIRI + bevacizumab initiation 10 . Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) 11 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 FOLFIRI + bevacizumab initiation anticipation need major surgical procedure course study 12 . Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior Day 1 FOLFIRI + bevacizumab initiation 13 . History abdominal fistula gastrointestinal perforation within 6 month prior Day 1 FOLFIRI + bevacizumab initiation 14 . Serious , nonhealing wound , active ulcer , untreated bone fracture 15 . Proteinuria demonstrate : Urine protein : creatinine ( UPC ) ratio ≥ 1.0 screening OR Urine dipstick proteinuria ≥ 2+ ( patient discover ≥2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate ≤ 1g protein 24 hour eligible ) 16 . Any serious uncontrolled medical disorder would impair ability subject receive protocoldriven therapy 17 . Other anticancer investigational therapy patient study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Colon Cancer</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>FOLFIRI</keyword>
	<keyword>Genotyping</keyword>
	<keyword>UGT1A1</keyword>
</DOC>